One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-148481
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
Affiliation: Dana-Farber Cancer Institute, Harvard University, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Mayo Clinic, University of Calgary, Institute of Cancer Research, Ghent University Hospital, Takeda (United States), Centre Hospitalier Universitaire de Lille, University of Lille, Centre Hospitalier Universitaire de Nantes, Japanese Red Cross Medical Center, Hôpital Lyon Sud, Rocky Mountain Cancer Centers, Hôpital André Mignot, Centre Hospitalier de Versailles, Centre Hospitalier Universitaire de Tours, University of Alberta, Emory University, Clinique Victor Hugo, Osaka University, Seoul National University Hospital
Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
